Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer |
| |
Authors: | Darcy V. Spicer Ann Kelley Robin Herman Grace Dean Lucy Stevenson Malcolm S. Mitchell |
| |
Affiliation: | (1) Department of Medicine, University of Southern California School of Medicine, and Kenneth Norris Jr. Comprehensive Cancer Center, Room 501, 1441 Eastlake Avenue, 90033 Los Angeles, CA, USA |
| |
Abstract: | Summary We undertook a preliminary study to examine the response rate of recombinant interleukin-2 (rIL-2) in patients with advanced measurable breast cancer, in a phase II clinical trial. The regimen we utilized was designed to allow outpatient administration. A treatment cycle consisted of low-dose cyclophosphamide (350 mg/m2) given on day -3 followed by the bolus administration of rIL-2 (3.6 × 106 Cetus units/m2) on days 1–5, and 8–12. Toxicity was significant but acceptable. One partial remission was seen in 13 evaluable patients. In 2 additional patients clear evidence of an antitumor response was observed. The study was terminated prematurely owing to a shortage of rIL-2. Additional evaluation of rIL-2 in breast cancer appears warranted. |
| |
Keywords: | Interleukin-2 Cytokines Breast cancer Immunotherapy |
本文献已被 SpringerLink 等数据库收录! |